drugset / Trial / NCT00631072
In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer
Phase 1
Completed
9 enrolled
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine whether we can purify and grow a population of cells from the participants blood (iNKT cells) and then safely give them back to the participant in increased numbers, and whether these cells will then stimulate the bodies own immune response against the cancer. These iNKT cells have been used in laboratory studies and information from these and other research studies suggest that increasing the number of these cells in the blood can stimulate the immune response against tumors.
Timeline
- Start
- 2008-02
- Primary completion
- 2014-08
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INKT | Cell therapy | — | Intravenous |
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |